MPXV eli Orthopox virus simiae- lajia on käytetty myös vektorin tavoin kutn adenovirusta rokotevalmistelun joissain vaiheissa.

 ESIMERKKI rokotevalmistelujen  vaiheista:

https://pubmed.ncbi.nlm.nih.gov/28792942/

 

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers

Silvia Capucci  ^{1   2} , Edmund G Wee  ¹ , Torben Schiffner  ³ , Celia C LaBranche  ⁴ , Nicola Borthwick  ¹ , Albert Cupo  ⁵ , Jonathan Dodd  ³ , Hansi Dean  ⁶ , Quentin Sattentau  ³ , David Montefiori  ⁴ , Per J Klasse  ⁵ , Rogier W Sanders  ^{5   7} , John P Moore  ⁵ , Tomáš Hanke  ^{1   8}

Affiliations

• PMID: 28792942
• PMCID: PMC5549892
• DOI: 10.1371/journal.pone.0181886

Free PMC article

Abstract

Rabbits and monkeys immunized with HIV type 1 (HIV-1) native-like BG505 SOSIP.664 (BG505s) glycoprotein trimers are known to induce antibodies that can neutralize the autologous tier-2 virus. Here, we assessed the induction of HIV-1 trimer binding and neutralizing antibody (nAb) titres when BG505s trimers were also delivered by non-replicating simian (chimpanzee) adenovirus and non-replicating poxvirus modified vaccinia virus Ankara (MVA) vaccine vectors. First, we showed that approximately two-thirds and one-third of the trimers secreted from the ChAdOx1.BG505s (C) and MVA.BG505s (M) vaccine-infected cells, respectively, were cleaved and in a native-like conformation. Rabbits were immunized intramuscularly with these vaccine vectors and in some cases boosted with ISCOMATRIX™-adjuvanted BG505s protein trimer (P), using CCC, MMM, PPP, CPP, MPP and CMP vaccine regimens. We found that the peak trimer-binding antibody and tier-1A and autologous tier-2 nAb responses induced by the CC, CM, PPP, CPP, MPP and CMP regimens were comparable, although only PPP induced autologous tier-2 nAbs in all the immunized animals. Three animals developed weak heterologous tier-2 nAbs. These results demonstrate that ChAdOx1 and MVA vectors are useful delivery modalities for not only T-cell, but also antibody vaccine development.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.